Caris Life Sciences, Inc. revenue
Caris Life Sciences, Inc.'s revenue was $812m in fiscal 2025, up 97.0% on the year before. Over the last twelve months it was $990m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Molecular Profiling Services | $767M | 94.4% | ▲ 119.6% |
| Pharma Research and Development Services | $45.3M | 5.6% | ▼ 28.2% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $801M | 98.7% | ▲ 99.4% |
| Outside the US | $10.6M | 1.3% | ▲ 2.1% |
From Caris Life Sciences, Inc.'s 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Caris Life Sciences, Inc. | $990m | 85.4% | — |
| Innovage Holding Corp. | $990m | 15.9% | 12.9% |
| Corvel Corp | $984m | 7.1% | 10.3% |
| Pennant Group, Inc. | $1.10bn | 37.9% | 30.0% |
| Guardant Health, Inc. | $1.18bn | 42.7% | 32.4% |
| U S Physical Therapy Inc | $812m | 11.3% | 11.8% |
Compare with peers
- Innovage Holding Corp. revenue
- Corvel Corp revenue
- Pennant Group, Inc. revenue
- Guardant Health, Inc. revenue
- U S Physical Therapy Inc revenue
Head to head: CAI vs INNVCAI vs CRVLCAI vs PNTG
More: Health Care Services stocks compared, Health Care sector, rankings of US companies